株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

エリスロポエチン産生促進剤:治療アプリケーションと世界市場

Erythropoietin Stimulating Agents: Therapeutic Applications and Global Markets

発行 BCC Research 商品コード 346499
出版日 ページ情報 英文 164 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: BCC Research社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
エリスロポエチン産生促進剤:治療アプリケーションと世界市場 Erythropoietin Stimulating Agents: Therapeutic Applications and Global Markets
出版日: 2016年01月01日 ページ情報: 英文 164 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界のエリスロポエチン産生促進剤 (ESA) 市場は、2015年から2020年にかけて0.2%のCAGRで推移し、市場規模は2015年の72億米ドルから2020年までに約73億米ドルへ拡大すると予測されています。

当レポートでは、世界のエリスロポエチン産生促進剤 (ESA) 市場について調査し、世界市場および治療アプリケーションの概要、米国・世界市場の動向分析とCAGR予測、エリスロポエチンの主要タイプ・主要地域・アプリケーション別に四つ市場規模の分析、がん治療・慢性肝疾患 (CKD) 治療・HIV治療・貧血治療を含むアプリケーション範囲の分析、市場・サプライヤー情勢に影響を及ぼす主な動向と課題、産業の発展と市場に影響を及ぼすバイオシミラーの到来、および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • 定義
  • 製剤としてのエリスロポエチン
  • エリスロポエチンの開発段階
  • エリスロポエチンのアプリケーション
  • エリスロポエチンの副作用
  • 製造手法のメリット・デメリット

第4章 R&D製剤のパイプライン

第5章 世界のエリスロポエチン製剤市場予測

  • 世界のエリスロポエチン製剤市場予測: カテゴリー別
  • 世界のエリスロポエチン製剤市場予測: タイプ別
  • 世界のエリスロポエチン生物製剤市場予測: タイプ別
  • 世界のエリスロポエチンバイオシミラー製剤市場予測: タイプ別
  • 世界のエリスロポエチン製剤市場予測: アプリケーション別
  • 世界のエリスロポエチン製剤市場予測: 地域別
  • 世界のエリスロポエチン製剤市場予測: 地域別
  • 世界のエリスロポエチン生物製剤市場予測: 地域別
  • 世界のエリスロポエチンバイオシミラー製剤市場予測: 地域別
  • 世界のエリスロポエチン製剤市場予測: アプリケーション別
  • 世界のエリスロポエチン製剤市場予測: アプリケーション別
  • 世界のエリスロポエチンバイオシミラー製剤市場予測: アプリケーション別
  • 世界のエポエチンアルファ製剤市場予測: 地域別
  • 世界のエポエチンベータ製剤市場予測: 地域別
  • 世界のエリスロポエチンダーベポエチンアルファ製剤市場予測: 地域別
  • 世界のその他のエリスロポエチン生物製剤市場予測:地域別
  • 世界の肝疾患向けエリスロポエチン製剤市場予測:地域別
  • 世界の癌疾患向けエリスロポエチン製剤市場予測:地域別
  • 世界のその他疾患向けエリスロポエチン製剤市場予測:地域別
  • 世界のエポエチンアルファ製剤市場予測: アプリケーション別
  • 世界のエポエチンベータ製剤市場予測: アプリケーション別
  • 世界のダーベポエチンアルファ製剤市場予測 アプリケーション別
  • 世界のその他のエリスロポエチン生物製剤市場予測: アプリケーション別
  • 世界市場の予測 EPOGEN 製剤:地域別
  • 世界市場の予測 EPOGEN 製剤:アプリケーション別
  • 世界市場の予測 PROCRIT 製剤:地域別
  • 世界市場の予測 PROCRIT 製剤:アプリケーション別
  • 世界市場の予測 EPREX 製剤:地域別
  • 世界市場の予測 EPREX 製剤:アプリケーション別
  • 世界市場の予測 ARANESP 製剤:地域別
  • 世界市場の予測 ARANESP 製剤:アプリケーション別
  • 世界市場の予測 NEORECORMON 製剤:地域別
  • 世界市場の予測 NEORECORMON 製剤:アプリケーション別
  • 世界市場の予測 MIRCERA 製剤:地域別
  • 世界市場の予測 MIRCERA アプリケーション別

第6章 促進因子・課題

  • 慢性肝疾患の事例増加
  • 癌有病率の増加
  • 血栓症および赤芽球癆 (PRCA) のリスク
  • ジェネリック医薬品競争の激化

第7章 ベンダー情勢・企業プロファイル

  • 3SBIO INC.
  • AMEGA BIOTECH
  • AMGEN INC.
  • BIOCON
  • BIOSIDUS
  • BLAUSIEGEL
  • CELON LABS
  • CENTER OF MOLECULAR IMMUNOLOGY
  • CHALVER LABORATORIES
  • CJ HEALTHCARE
  • CLARIS LIFESCIENCES
  • DR. REDDY'S LABORATORIES.
  • EMCURE PHARMACEUTICALS
  • HINDUSTAN ANTIBIOTICS
  • HOSPIRA INC.
  • JCR PHARMACEUTICALS CO. LTD.
  • JOHNSON & JOHNSON
  • LANDSTEINER SCIENTIFIC S.A. DE C.V.
  • LA RENON HEALTHCARE
  • LG LIFE SCIENCES
  • LUPIN LTD.
  • MEDICE DRUG PUTTER GMBH & CO. KG
  • NOVARTIS INTERNATIONAL AG
  • PANACEA BIOTEC
  • PROBIOMED
  • RELIANCE LIFE SCIENCES
  • ROCHE
  • RPG LIFE SCIENCES
  • SERUM INSTITUTE OF INDIA
  • SHANGHAI CHEMO WANBANG BIOPHARMA CO. LTD.
  • SHANTHA BIOTECHNICS
  • STADA ARZNEIMITTEL AG
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • VHB LIFE SCIENCES LTD.
  • WOCKHARDT LIMITED
  • ZUVENTUS HEALTH CARE
  • ZYDUS CADILA HEALTHCARE

図表

目次
Product Code: PHM130A

The global market for erythropoietin stimulating agents (ESAs) will grow from nearly $7.2 billion in 2015 to nearly $7.3 billion by 2020 with a compound annual growth rate (CAGR) of 0.2% for the period 2015-2020.

This report provides:

  • An overview of the global markets and therapeutic applications for erythropoietin stimulating agents (ESAs).
  • Analyses of U.S. as well as international market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
  • Coverage of the market in value terms broken down by major types of erythropoietin, by major regions, and by applications.
  • Coverage of applications including cancer therapy, chronic kidney disease (CKD) therapy, HIV therapy, and anemia therapy.
  • Major trends and challenges affecting the market and the supplier landscape.
  • A look at industrial developments and the advent of biosimilars impacting the market.
  • Analysis of the risks associated with the market for abusive uses of ESAa and their adverse effects.
  • Profiles of major players in the industry.

image1

REPORT SCOPE

SCOPE OF REPORT

The scope of this report is broad and covers erythropoietin drug used globally in various types of applications. The market is broken down in terms of the various types of erythropoietin drug by region and by applications. Revenue forecasts from 2015 to 2020 are given for erythropoietin drug, with its applications and regional markets.

The report also includes a discussion of the major players in each of the regional markets for erythropoietin drug. It explains the major market drivers of the global erythropoietin drug industry, the current trends within the industry, major industry challenges and the regional dynamics of the global erythropoietin drug market. The report concludes with a special focus on the supplier landscape. It includes detailed profiles of the major vendors in the erythropoietin drug industry globally.

ANALYSTS' CREDENTIALS

This report has been developed by the market research analysts at Bizimpact Knowledge Services LLP, a market research and services company. The project has been managed by Aneesh Kumar, a partner in the company, along with input from various subject-matter experts. Aneesh Kumar has more than seven years experience in handling various custom research projects and has worked with a multinational company on various research assignments on global markets.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • RESEARCH METHODOLOGY
  • ANALYSTS' CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, 2014-2020 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • DEFINITION
  • ERYTHROPOIETIN AS A DRUG
  • DEVELOPMENTAL STAGES OF ERYTHROPOIETIN
  • APPLICATIONS OF ERYTHROPOIETIN
  • SIDE EFFECTS OF ERYTHROPOIETIN
    • CARDIOVASCULAR
    • HEMATOLOGIC
    • CENTRAL NERVOUS SYSTEM
    • PSYCHIATRIC
    • ONCOLOGIC
    • GASTROINTESTINAL
    • DERMATOLOGIC
  • PROS AND CONS OF MANUFACTURING METHODS:
    • PROS
    • CONS

CHAPTER 4 R&D DRUG PIPELINE

  • TABLE 1 MAJOR EPO R &D DRUG PIPELINE BY TRIAL PHASE

CHAPTER 5 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUG

  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY CATEGORY
  • TABLE 2 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY CATEGORY, THROUGH 2020 ($ MILLIONS)
  • FIGURE 1 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY CATEGORY, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY TYPE
  • TABLE 3 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • FIGURE 2 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY TYPE, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE
  • TABLE 4 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • FIGURE 3 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE
  • TABLE 5 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • FIGURE 4 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION
  • TABLE 6 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 5 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION
  • TABLE 7 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 6 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION
    • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUG MARKET BY REGION
    • TABLE 8 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 7 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)
    • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION
    • TABLE 9 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 8 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION
    • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION
    • TABLE 10 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 9 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, 2015 AND 2020 (%)
    • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION
    • TABLE 11 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 10 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPOETIN-ALFA DRUGS BY REGION
  • TABLE 12 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 11 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPOETIN-BETA DRUGS BY REGION
  • TABLE 13 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 12 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION
  • TABLE 14 GLOBAL MARKET FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 13 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR OTHER ERYTHROPOIETINBIOLOGIC DRUGS BY REGION
  • TABLE 15 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 14 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION
  • TABLE 16 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 15 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY DISEASES BY REGION
  • TABLE 17 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS ONCOLOGY DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 16 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY DISEASES BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION
  • TABLE 18 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 17 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPOETIN-ALFA DRUGS BY APPLICATION
  • TABLE 19 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 18 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPOETIN-BETA DRUGS BY APPLICATION
  • TABLE 20 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 19 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR DARBEPOETIN-ALFA BY APPLICATION
  • TABLE 21 GLOBAL MARKET FOR DARBEPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 20 GLOBAL MARKET SHARE FOR DARBEPPOIETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION
  • TABLE 22 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 21 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPOGEN DRUGS BY REGION
  • TABLE 23 GLOBAL MARKET FOR EPOGEN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 22 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPOGEN DRUGS BY APPLICATION
  • TABLE 24 GLOBAL MARKET FOR EPOGEN DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 23 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR PROCRIT DRUGS BY REGION
  • TABLE 25 GLOBAL MARKET FOR PROCRIT DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 24 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR PROCRIT DRUGS BY APPLICATION
  • TABLE 26 GLOBAL MARKET FOR PROCRIT DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 25 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPREX DRUGS BY REGION
  • TABLE 27 GLOBAL MARKET FOR EPREX DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 26 GLOBAL MARKET SHARE FOR EPREX DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPREX DRUGS BY APPLICATION
  • TABLE 28 GLOBAL MARKET FOR EPREX DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 27 GLOBAL MARKET SHARE FOR EPREX DRUGS BY APPLICATION, 2015 AND 2020 (%) 7
  • GLOBAL MARKET FORECAST FOR ARANESP DRUGS BY REGION
  • TABLE 29 GLOBAL MARKET FOR ARANESP DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 28 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ARANESP DRUGS BY APPLICATION
  • TABLE 30 GLOBAL MARKET FOR ARANESP DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 29 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR NEORECORMON DRUGS BY REGION
  • TABLE 31 GLOBAL MARKET FOR NEORECORMON DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 30 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR NEORECORMON DRUGS BY APPLICATION
  • TABLE 32 GLOBAL MARKET FOR NEORECORMON DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 31 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR MIRCERA DRUGS BY REGION
  • TABLE 33 GLOBAL MARKET FOR MIRCERA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 32 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR MIRCERA BY APPLICATION
  • TABLE 34 GLOBAL MARKET FOR MIRCERA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 33 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY APPLICATION, 2015 AND 2020 (%)

CHAPTER 6 DRIVERS AND CHALLENGES

  • INCREASING CASES OF CHRONIC KIDNEY DISEASE
    • DIABETES
    • FIGURE 34 NUMBER OF PEOPLE AGES 20 TO 79 WITH DIABETES, BY REGION, 2013 AND 2035 (MILLIONS)
    • FIGURE 35 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES BY TOP TEN COUNTRIES, 2013 (MILLIONS)
    • FIGURE 36 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES, BY TOP TEN COUNTRIES, 2035 (MILLIONS)
    • FIGURE 37 NUMBER OF AMERICANS DIAGNOSED WITH DIABETES, 2009-2013 (MILLIONS)
    • HYPERTENSION
    • FIGURE 38 PREVALENCE OF HYPERTENSION IN PEOPLE AGED ABOVE 25 YEARS BY REGION, 2008 AND 2014
    • TABLE 35 GLOBAL PREVALENCE OF HYPERTENSION BY REGION, 2000-2025 (MILLIONS)
    • TABLE 36 U.S. INCIDENT OF ESRD BASED ON DISEASES, 2011 AND 2012 (MILLIONS)
    • TABLE 37 GLOBAL POPULATION OVER THE AGE OF 60, THROUGH 2020 (MILLIONS)
    • TABLE 38 U.S. INCIDENT OF ESRD BASED ON ETHNICITY, 2011 AND 2012 (MILLIONS)
  • INCREASING PREVALENCE OF CANCER
  • FIGURE 39 GLOBAL CANCER PREVALENCE BY TYPE, 2012 (%)
  • FIGURE 40 GLOBAL CANCER PREVALENCE BASED ON FIVE YEAR PERIOD BY TYPE, 2008-2012 (%) 15
  • FIGURE 41 CANCER PREVALENCE IN MORE DEVELOPED REGIONS BY TYPE, 2012 (%)
  • FIGURE 42 CANCER PREVALENCE BASED ON FIVE YEAR PERIOD IN MORE DEVELOPED REGIONS BY TYPE, 2008-2012 (%)
  • FIGURE 43 CANCER PREVALENCE IN LESS DEVELOPED REGIONS BY TYPE, 2012 (%)
  • FIGURE 44 CANCER PREVALENCE BASED ON FIVE-YEAR PERIOD IN LESS DEVELOPED REGIONS BY TYPE, 2008-2012 (%)
  • TABLE 39 INCIDENCE OF ANEMIA BY CHEMOTHERAPY AGENTS
  • RISK OF THROMBOSIS AND PURE RED CELL APLASIA (PRCA)
    • CARDIOVASCULAR PROBLEMS
    • THROMBOSIS IN CANCER PATIENTS
    • INCREASED TUMOR PROGRESSION
    • ZIVODUINE TREATED HIV INFECTED PATIENTS
    • PURE RED CELL APLASIA
  • INCREASING GENERIC COMPETITION
    • SYNTHETIC ERYTHROPOIETIN
    • TRANSFORMING GROWTH FACTOR BETA SUPERFAMILY

CHAPTER 7 VENDOR LANDSCAPE AND COMPANY PROFILES

  • TABLE 40 GLOBAL ERYTHROPOIETIN BIOLOGIC DRUGS MARKET SHARE BY MANUFACTURER, 2014 (%/$ MILLIONS)
  • 3SBIO INC.
  • TABLE 41 3SBIO'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • AMEGA BIOTECH
  • AMGEN INC.
  • TABLE 42 AMGEN'S ERYTHROPOETIN DRUGS PIPELINE
  • TABLE 43 AMGEN'S ERYTHROPOETIN DRUGS PATENTS
  • TABLE 44 ARANESP'S SALES BY REGION, THROUGH 2014 ($ MILLIONS)
  • TABLE 45 EPOGEN'S SALES BY REGION, 2011-2014 ($ MILLIONS)
  • TABLE 46 AMGEN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 45 AMGEN'S REVENUE BY REGION, 2014 (%)
  • FIGURE 46 AMGEN'S SALES BY PRODUCT, 2014 (%)
  • BIOCON
  • FIGURE 47 BIOCON'S SALES BY REGION, 2014 (%)
  • TABLE 47 BIOCON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 48 BIOCON'S SALES BY BUSINESS SEGMENT, 2014 (%)
  • BIOSIDUS
  • BLAUSIEGEL
  • CELON LABS
  • CENTER OF MOLECULAR IMMUNOLOGY
  • CHALVER LABORATORIES
  • CJ HEALTHCARE
  • CLARIS LIFESCIENCES
  • TABLE 48 CLARIS LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • DR. REDDY'S LABORATORIES.
  • FIGURE 49 DR.REDDY'S SALES BY SEGMENT, 2013-2014 (%)
  • TABLE 49 DR. REDDY'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • EMCURE PHARMACEUTICALS
  • HINDUSTAN ANTIBIOTICS
  • HOSPIRA INC.
  • TABLE 50 HOSPIRA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 50 HOSPIRA'S SALES BY REGION, 2014
  • FIGURE 51 HOSPIRA'S SALES BY BUSINESS SEGMENT, 2014 (%)
  • INTAS BIOPHARMACEUTICAL LTD
  • TABLE 51 INTAS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 52 INTAS' SALES BY REGION, 2014 (%)
  • JCR PHARMACEUTICALS CO. LTD.
  • TABLE 52 JCR PHARMACEUTICALS' RECENT FINANCIAL PERFORMANCE, THROUGH 2015 ($ MILLIONS)
  • FIGURE 53 JCR PHARMACEUTICALS' THERAPEUTIC CONTRIBUTION, 2013-2014 (%)
  • JOHNSON & JOHNSON
  • TABLE 53 JOHNSON & JOHNSON'S ERYTHROPOETIN SALES, THROUGH 2014 ($ MILLIONS)
  • FIGURE 54 JOHNSON & JOHNSON'S SALES BY SEGMENT, 2014 (%)
  • TABLE 54 JOHNSON & JOHNSON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • LANDSTEINER SCIENTIFIC S.A. DE C.V.
  • LA RENON HEALTHCARE
  • LG LIFE SCIENCES
  • TABLE 55 LG LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • LUPIN LTD.
  • TABLE 56 LUPIN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 55 LUPIN'S SALES BY REGION, 2014 (%)
  • MEDICE DRUG PUTTER GMBH & CO. KG
  • NOVARTIS INTERNATIONAL AG
  • TABLE 57 NOVARTIS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 56 NOVARTIS' SALES SHARE BY BUSINESS SEGMENTS, 2014 (%)
  • FIGURE 57 NOVARTIS' INTERNATIONAL AG SALES BY REGION, 2014 (%)
  • PANACEA BIOTEC
  • TABLE 58 COMPOSITIONS OF ERYTHROPOIETIN MANUFACTURED BY PANACEA
  • TABLE 59 PANACEA BIOTEC'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 58 PANACEA BIOTEC'S SALES BY REGION, 2014 (%)
  • PROBIOMED
  • RELIANCE LIFE SCIENCES
  • ROCHE
  • TABLE 60 ROCH'S ERYTHROPOETIN SALES BY PRODUCT, THROUGH 2014 ($ MILLIONS)
  • TABLE 61 NEORECORMON/EPOGIN SALES BY REGION, THROUGH 2014 ($ MILLIONS)
  • TABLE 62 MIRCERA SALES BY REGION, THROUGH 2014 ($ MILLIONS)
  • TABLE 63 ROCHE'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • RPG LIFE SCIENCES
  • TABLE 64 RPG LIFESCIENCES RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 59 RPG LIFESCIENCES' SALES BY BUSINESS SEGMENT, 2014 (%)
  • FIGURE 60 RPG LIFESCIENCES' SALES BY REGION, 2014 (%)
  • SERUM INSTITUTE OF INDIA
  • SHANGHAI CHEMO WANBANG BIOPHARMA CO. LTD.
  • SHANTHA BIOTECHNICS
  • STADA ARZNEIMITTEL AG
  • TABLE 65 STADA ARZNEIMITTEL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 61 STADA ARZNEIMITTEL'S THERAPEUTIC CONTRIBUTION, 2014 (%)
  • FIGURE 62 STADA ARZNEIMITTEL'S SALES BY REGION, 2014 ($ MILLIONS)
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TABLE 66 SUN PHARMACEUTICAL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 63 SUN PHARMACEUTICAL'S SALES BY REGION, 2014 (%)
  • FIGURE 64 SUN PHARMACEUTICAL'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • TABLE 67 TEVA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 65 TEVA'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)
  • FIGURE 66 TEVA'S SALES BY REGION, 2014 (%)
  • VHB LIFE SCIENCES LTD.
  • WOCKHARDT LIMITED
  • FIGURE 67 WOCKHARDT'S SALES BY REGION, 2014 (%)
  • TABLE 68 WOCKHARDT'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • ZUVENTUS HEALTH CARE
  • ZYDUS CADILA HEALTHCARE
  • TABLE 69 ZYDUS CADILA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • FIGURE 68 ZYDUS CADILA'S SALES BY REGION, 2014 (%)

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 1 MAJOR EPO R &D DRUG PIPELINE BY TRIAL PHASE
  • TABLE 2 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY CATEGORY, THROUGH 2020 ($ MILLIONS)
  • TABLE 3 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 4 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 5 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 6 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 7 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 8 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 9 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 10 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 11 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 12 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 13 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 14 GLOBAL MARKET FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 15 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 16 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 17 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS ONCOLOGY DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 18 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 19 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 20 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 21 GLOBAL MARKET FOR DARBEPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 22 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 23 GLOBAL MARKET FOR EPOGEN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 24 GLOBAL MARKET FOR EPOGEN DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 25 GLOBAL MARKET FOR PROCRIT DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 26 GLOBAL MARKET FOR PROCRIT DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 27 GLOBAL MARKET FOR EPREX DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 28 GLOBAL MARKET FOR EPREX DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 29 GLOBAL MARKET FOR ARANESP DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 30 GLOBAL MARKET FOR ARANESP DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 31 GLOBAL MARKET FOR NEORECORMON DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 32 GLOBAL MARKET FOR NEORECORMON DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 33 GLOBAL MARKET FOR MIRCERA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 34 GLOBAL MARKET FOR MIRCERA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 35 GLOBAL PREVALENCE OF HYPERTENSION BY REGION, 2000-2025 (MILLIONS)
  • TABLE 36 U.S. INCIDENT OF ESRD BASED ON DISEASES, 2011 AND 2012 (MILLIONS)
  • TABLE 37 GLOBAL POPULATION OVER THE AGE OF 60, THROUGH 2020 (MILLIONS)
  • TABLE 38 U.S. INCIDENT OF ESRD BASED ON ETHNICITY, 2011 AND 2012 (MILLIONS)
  • TABLE 39 INCIDENCE OF ANEMIA BY CHEMOTHERAPY AGENTS
  • TABLE 40 GLOBAL ERYTHROPOIETIN BIOLOGIC DRUGS MARKET SHARE BY MANUFACTURER, 2014 (%/$ MILLIONS)
  • TABLE 41 3SBIO'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 42 AMGEN'S ERYTHROPOETIN DRUGS PIPELINE
  • TABLE 43 AMGEN'S ERYTHROPOETIN DRUGS PATENTS
  • TABLE 44 ARANESP'S SALES BY REGION, THROUGH 2014 ($ MILLIONS)
  • TABLE 45 EPOGEN'S SALES BY REGION, 2011-2014 ($ MILLIONS)
  • TABLE 46 AMGEN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 47 BIOCON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 48 CLARIS LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 49 DR. REDDY'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • TABLE 50 HOSPIRA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 51 INTAS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 52 JCR PHARMACEUTICALS' RECENT FINANCIAL PERFORMANCE, THROUGH 2015 ($ MILLIONS)
  • TABLE 53 JOHNSON & JOHNSON'S ERYTHROPOETIN SALES, THROUGH 2014 ($ MILLIONS)
  • TABLE 54 JOHNSON & JOHNSON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 55 LG LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • TABLE 56 LUPIN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 57 NOVARTIS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 58 COMPOSITIONS OF ERYTHROPOIETIN MANUFACTURED BY PANACEA
  • TABLE 59 PANACEA BIOTEC'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 60 ROCH'S ERYTHROPOETIN SALES BY PRODUCT, THROUGH 2014 ($ MILLIONS)
  • TABLE 61 NEORECORMON/EPOGIN SALES BY REGION, THROUGH 2014 ($ MILLIONS)
  • TABLE 62 MIRCERA SALES BY REGION, THROUGH 2014 ($ MILLIONS)
  • TABLE 63 ROCHE'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 64 RPG LIFESCIENCES RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 65 STADA ARZNEIMITTEL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 66 SUN PHARMACEUTICAL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 67 TEVA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 68 WOCKHARDT'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • TABLE 69 ZYDUS CADILA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, 2014-2020 ($ MILLIONS)
  • FIGURE 1 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY CATEGORY, 2015 AND 2020 (%)
  • FIGURE 2 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY TYPE, 2015 AND 2020 (%)
  • FIGURE 3 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, 2015 AND 2020 (%)
  • FIGURE 4 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, 2015 AND 2020 (%)
  • FIGURE 5 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 6 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 7 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 8 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 9 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 10 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 11 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 12 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 13 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 14 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 15 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, 2015 AND 2020 (%)
  • FIGURE 16 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY DISEASES BY REGION, 2015 AND 2020 (%)
  • FIGURE 17 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, 2015 AND 2020 (%)
  • FIGURE 18 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 19 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 20 GLOBAL MARKET SHARE FOR DARBEPPOIETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 21 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 22 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 23 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 24 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 25 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 26 GLOBAL MARKET SHARE FOR EPREX DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 27 GLOBAL MARKET SHARE FOR EPREX DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 28 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 29 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 30 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 31 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 32 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 33 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 34 NUMBER OF PEOPLE AGES 20 TO 79 WITH DIABETES, BY REGION, 2013 AND 2035 (MILLIONS)
  • FIGURE 35 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES BY TOP TEN COUNTRIES, 2013 (MILLIONS)
  • FIGURE 36 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES, BY TOP TEN COUNTRIES, 2035 (MILLIONS)
  • FIGURE 37 NUMBER OF AMERICANS DIAGNOSED WITH DIABETES, 2009-2013 (MILLIONS)
  • FIGURE 38 PREVALENCE OF HYPERTENSION IN PEOPLE AGED ABOVE 25 YEARS BY REGION, 2008 AND 2014
  • FIGURE 39 GLOBAL CANCER PREVALENCE BY TYPE, 2012 (%)
  • FIGURE 40 GLOBAL CANCER PREVALENCE BASED ON FIVE YEAR PERIOD BY TYPE, 2008-2012 (%)
  • FIGURE 41 CANCER PREVALENCE IN MORE DEVELOPED REGIONS BY TYPE, 2012 (%)
  • FIGURE 42 CANCER PREVALENCE BASED ON FIVE YEAR PERIOD IN MORE DEVELOPED REGIONS BY TYPE, 2008-2012 (%)
  • FIGURE 43 CANCER PREVALENCE IN LESS DEVELOPED REGIONS BY TYPE, 2012 (%)
  • FIGURE 44 CANCER PREVALENCE BASED ON FIVE-YEAR PERIOD IN LESS DEVELOPED REGIONS BY TYPE, 2008-2012 (%)
  • FIGURE 45 AMGEN'S REVENUE BY REGION, 2014 (%)
  • FIGURE 46 AMGEN'S SALES BY PRODUCT, 2014 (%)
  • FIGURE 47 BIOCON'S SALES BY REGION, 2014 (%)
  • FIGURE 48 BIOCON'S SALES BY BUSINESS SEGMENT, 2014 (%)
  • FIGURE 49 DR.REDDY'S SALES BY SEGMENT, 2013-2014 (%)
  • FIGURE 50 HOSPIRA'S SALES BY REGION, 2014
  • FIGURE 51 HOSPIRA'S SALES BY BUSINESS SEGMENT, 2014 (%)
  • FIGURE 52 INTAS' SALES BY REGION, 2014 (%)
  • FIGURE 53 JCR PHARMACEUTICALS' THERAPEUTIC CONTRIBUTION, 2013-2014 (%)
  • FIGURE 54 JOHNSON & JOHNSON'S SALES BY SEGMENT, 2014 (%)
  • FIGURE 55 LUPIN'S SALES BY REGION, 2014 (%)
  • FIGURE 56 NOVARTIS' SALES SHARE BY BUSINESS SEGMENTS, 2014 (%)
  • FIGURE 57 NOVARTIS' INTERNATIONAL AG SALES BY REGION, 2014 (%)
  • FIGURE 58 PANACEA BIOTEC'S SALES BY REGION, 2014 (%)
  • FIGURE 59 RPG LIFESCIENCES' SALES BY BUSINESS SEGMENT, 2014 (%)
  • FIGURE 60 RPG LIFESCIENCES' SALES BY REGION, 2014 (%)
  • FIGURE 61 STADA ARZNEIMITTEL'S THERAPEUTIC CONTRIBUTION, 2014 (%)
  • FIGURE 62 STADA ARZNEIMITTEL'S SALES BY REGION, 2014 ($ MILLIONS)
  • FIGURE 63 SUN PHARMACEUTICAL'S SALES BY REGION, 2014 (%)
  • FIGURE 64 SUN PHARMACEUTICAL'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)
  • FIGURE 65 TEVA'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)
  • FIGURE 66 TEVA'S SALES BY REGION, 2014 (%)
  • FIGURE 67 WOCKHARDT'S SALES BY REGION, 2014 (%)
  • FIGURE 68 ZYDUS CADILA'S SALES BY REGION, 2014 (%)
Back to Top